TY - JOUR
T1 - Clinical Risk Assessment and Prediction in Congenital Heart Disease Across the Lifespan
T2 - JACC Scientific Statement
AU - Opotowsky, Alexander R.
AU - Khairy, Paul
AU - Diller, Gerhard
AU - Kasparian, Nadine A.
AU - Brophy, James
AU - Jenkins, Kathy
AU - Lopez, Keila N.
AU - McCoy, Alison
AU - Moons, Philip
AU - Ollberding, Nicholas J.
AU - Rathod, Rahul H.
AU - Rychik, Jack
AU - Thanassoulis, George
AU - Vasan, Ramachandran S.
AU - Marelli, Ariane
N1 - Publisher Copyright:
© 2024 American College of Cardiology Foundation
PY - 2024/5/28
Y1 - 2024/5/28
N2 - Congenital heart disease (CHD) comprises a range of structural anomalies, each with a unique natural history, evolving treatment strategies, and distinct long-term consequences. Current prediction models are challenged by generalizability, limited validation, and questionable application to extended follow-up periods. In this JACC Scientific Statement, we tackle the difficulty of risk measurement across the lifespan. We appraise current and future risk measurement frameworks and describe domains of risk specific to CHD. Risk of adverse outcomes varies with age, sex, genetics, era, socioeconomic status, behavior, and comorbidities as they evolve through the lifespan and across care settings. Emerging technologies and approaches promise to improve risk assessment, but there is also need for large, longitudinal, representative, prospective CHD cohorts with multidimensional data and consensus-driven methodologies to provide insight into time-varying risk. Communication of risk, particularly with patients and their families, poses a separate and equally important challenge, and best practices are reviewed.
AB - Congenital heart disease (CHD) comprises a range of structural anomalies, each with a unique natural history, evolving treatment strategies, and distinct long-term consequences. Current prediction models are challenged by generalizability, limited validation, and questionable application to extended follow-up periods. In this JACC Scientific Statement, we tackle the difficulty of risk measurement across the lifespan. We appraise current and future risk measurement frameworks and describe domains of risk specific to CHD. Risk of adverse outcomes varies with age, sex, genetics, era, socioeconomic status, behavior, and comorbidities as they evolve through the lifespan and across care settings. Emerging technologies and approaches promise to improve risk assessment, but there is also need for large, longitudinal, representative, prospective CHD cohorts with multidimensional data and consensus-driven methodologies to provide insight into time-varying risk. Communication of risk, particularly with patients and their families, poses a separate and equally important challenge, and best practices are reviewed.
KW - congenital heart disease
KW - risk assessment
KW - risk prediction
UR - http://www.scopus.com/inward/record.url?scp=85192984723&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85192984723&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2024.02.055
DO - 10.1016/j.jacc.2024.02.055
M3 - Review article
C2 - 38777512
AN - SCOPUS:85192984723
SN - 0735-1097
VL - 83
SP - 2092
EP - 2111
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 21
ER -